DiaMedica Therapeutics, Inc. (DMAC)
6.39
-0.36
(-5.33%)
USD |
NASDAQ |
Aug 28, 16:00
6.39
0.00 (0.00%)
After-Hours: 20:00
DiaMedica Therapeutics Enterprise Value : 301.27M for Aug. 28, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 28, 2026 | 301.27M |
| August 27, 2026 | 320.68M |
| August 26, 2026 | 317.98M |
| August 25, 2026 | 320.14M |
| August 24, 2026 | 308.28M |
| August 21, 2026 | 308.28M |
| August 20, 2026 | 308.28M |
| August 19, 2026 | 323.92M |
| August 18, 2026 | 313.13M |
| August 17, 2026 | 313.67M |
| August 14, 2026 | 316.90M |
| August 13, 2026 | 320.68M |
| August 12, 2026 | 325.53M |
| August 11, 2026 | 327.15M |
| August 10, 2026 | 315.29M |
| August 07, 2026 | 320.68M |
| August 06, 2026 | 321.76M |
| August 05, 2026 | 316.10M |
| August 04, 2026 | 309.36M |
| August 03, 2026 | 308.28M |
| July 31, 2026 | 298.57M |
| July 30, 2026 | 307.74M |
| July 29, 2026 | 297.49M |
| July 28, 2026 | 314.75M |
| July 27, 2026 | 320.14M |
| Date | Value |
|---|---|
| July 24, 2026 | 319.87M |
| July 23, 2026 | 324.45M |
| July 22, 2026 | 330.66M |
| July 21, 2026 | 338.48M |
| July 20, 2026 | 334.70M |
| July 17, 2026 | 350.34M |
| July 16, 2026 | 341.17M |
| July 15, 2026 | 368.67M |
| July 14, 2026 | 357.35M |
| July 13, 2026 | 360.58M |
| July 10, 2026 | 370.29M |
| July 09, 2026 | 372.45M |
| July 08, 2026 | 385.93M |
| July 07, 2026 | 387.55M |
| July 06, 2026 | 388.63M |
| July 02, 2026 | 367.59M |
| July 01, 2026 | 357.89M |
| June 30, 2026 | 336.32M |
| June 29, 2026 | 337.92M |
| June 26, 2026 | 301.82M |
| June 25, 2026 | 280.26M |
| June 24, 2026 | 291.58M |
| June 23, 2026 | 287.27M |
| June 22, 2026 | 266.25M |
| June 18, 2026 | 264.10M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 4.128B |
| Alnylam Pharmaceuticals, Inc. | 31.39B |
| Anika Therapeutics, Inc. | 269.22M |
| Savara, Inc. | 937.77M |
| Vericel Corp. | 2.028B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.14M |
| Total Expenses (Quarterly) | 10.14M |
| EPS Diluted (Quarterly) | -0.1881 |
| Earnings Yield | -11.17% |
| Normalized Earnings Yield | -11.17 |